Gain Therapeutics, Inc. - GANX STOCK NEWS

Gain Therapeutics (NASDAQ: GANX) announced its participation in key investor and scientific conferences, emphasizing its commitment to neurodegenerative disease research. CEO Eric Richman will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, with a webcast available for investors. Additionally, Gain will showcase scientific data at the AD/PD™ 2022 Conference, running from March 15-20, 2022, and sponsor the Krabbe Translational Research Network Meeting from March 15-18, 2022. The company focuses on innovative treatments using its SEE-Tx™ platform.

Gain Therapeutics (NASDAQ: GANX) has unveiled promising pre-clinical data on its Gaucher Disease program at the 18th Annual WORLDSymposium. The study demonstrated that its STARs compounds significantly increase GCase protein levels, diminish inflammatory cytokines, and enhance lysosomal functions in GD-iPSC-derived dopaminergic neurons. These findings validate the company’s drug discovery platform, SEE-Tx®, and indicate potential for a first-in-class therapy. Gain aims to commence IND-enabling studies in Q4 2022, addressing unmet needs in neuronopathic Gaucher Disease treatment.

Gain Therapeutics (Nasdaq: GANX) held its inaugural R&D day webinar, highlighting its advancements in drug discovery through the SEE-Tx platform. The company focuses on developing treatments for GBA1 Parkinson's and Gaucher diseases, alongside other lysosomal storage disorders and metabolic diseases. Key 2022 priorities include initiating a Phase 1 trial for GBA1 Parkinson's and advancing its Gaucher disease program. Their innovative approach leverages new computational methods to identify allosteric targets and accelerate drug discovery.

Gain Therapeutics (Nasdaq: GANX) announced its upcoming R&D Day on February 4, 2022, focusing on utilizing computational technology for allosteric drug discovery. The event will feature expert presentations discussing advancements in targeting undruggable proteins, including key topics on neurodegenerative diseases and oncology. Gain's proprietary SEE-Tx® Platform aims to transform drug discovery by identifying novel allosteric targets. The event is expected to shed light on Gain's pipeline and recent research data relevant to treatments for conditions like Parkinson's and Gaucher Disease.

Gain Therapeutics (Nasdaq: GANX), a biotechnology company, has announced an upcoming R&D Day Event and participation in significant scientific conferences addressing neurodegenerative diseases. The R&D Day, titled "Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable", is scheduled for February 4, 2022, at 10:00 a.m. ET. Additionally, Gain will be present at the 18th Annual WORLDSymposium from February 7-11, 2022, and the AD/PD™ 2022 Conference from March 15-20, 2022.

Gain Therapeutics, Inc. (Nasdaq: GANX) announced CEO Eric Richman will participate in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. This virtual event will enable investor access via webcast, available for 90 days post-event. Gain Therapeutics focuses on innovative drug discovery, particularly targeting allosteric binding sites related to neurodegenerative diseases and lysosomal storage disorders. Supported by notable foundations and programs, the company aims to provide new treatment options for challenging disorders linked to protein misfolding.

Gain Therapeutics, Inc. (Nasdaq: GANX) granted Chief Operating Officer Matthias Alder an option to purchase 200,000 shares and 200,000 restricted stock units. These incentives, part of the 2021 Inducement Equity Incentive Plan, aim to motivate Alder upon joining the company. The options will vest over four years, with a $5.86 exercise price per share, matching the closing stock price on December 22, 2021. The restricted units' vesting is contingent on business and clinical milestones. Gain focuses on innovative treatments for neurodegenerative diseases.

Gain Therapeutics (Nasdaq: GANX) provided a scientific update on its Krabbe disease program, highlighting statistically significant increases in the GALC enzyme and a reduction in toxic substrate psychosine. This breakthrough suggests potential treatment options for patients with Krabbe disease, a severe genetic disorder affecting the nervous system. Initial tests on compounds showed promise in reducing psychosine levels. The next phase involves further evaluation of compounds in complex in vitro models.

Gain Therapeutics, Inc. (Nasdaq: GANX) will present a corporate overview at the Imagine AI + Healthcare Investor Summit on December 7, 2021. CEO Eric Richman and Chief Scientific Officer Xavier Barril, Ph.D., will discuss Gain's innovative approach to targeting allosteric binding sites for neurodegenerative diseases and lysosomal storage disorders. The summit is an opportunity for investors to engage with various companies and learn about advancements in AI within healthcare.